FDA-approved GLP-1 receptor agonists include: - Semaglutide (Rybelsus, Ozempic, Wegovy) - Exenatide (Bydureon BCise, Byetta) - Lixisenatide (Adlyxin) - Lixisenatide/insulin glargine (Soliqua) - Liraglutide (Saxenda, Victoza) - Liraglutide/insulin degludec (Xultophy) - Dulaglutide (Trulicity) - Tirzepatide (Mounjaro) For example, Ozempic (semaglutide) is approved for type 2 diabetes, while Wegovy (also semaglutide) is approved for obesity and overweight conditions with related health concerns
That means nasal dosing often needs to consider a slightly higher dose (or more frequent spritz) to match systemic exposure from injection
Animal experiments
While fatigue is among the most common side effects of Wegovy, it is less prevalent than gastrointestinal side effects such as nausea, diarrhea, vomiting, and constipation
Timeline: When to Expect Results on Tirzepatide Tirzepatide reaches steady state in 4 to 5 weeks at each dose level
Glutathione IV therapy is becoming increasingly popular due to its potential health benefits
